Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Neurosyphilis Market size was over USD 1.7 billion in 2024 and is estimated to reach USD 3.7 billion by the end of 2037, expanding at a CAGR of 6.8% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of neurosyphilis is evaluated at USD 1.8 billion.
The rising population of HIV patients, who are at high risk of developing infection in central nervous system (CNS) diseases is driving growth in the market. According to a WHO report, the number of HIV-infected people around the world reached 39.9 million in 2023. In the same year, the amounts of new and death cases were reported to be 1.3 million and 630,000 respectively. This advanced progression of syphilis, where the brain is affected, is nowadays frequently diagnosed among patients with HIV infections. Thus, there is a surge for early intervention to fight the threat of reaching this condition among these suffering individuals.
Prevalence of HIV in Various Demographics (WHO 2023)
|
Patient Demography |
Number of Infected Patients (in million) |
Number of New Cases |
Number of Death Cases |
|
Women (15+ years) |
20.5 |
520,000 |
240,000 |
|
Men (15+ years) |
18.1 |
660,000 |
320,000 |
|
Children (<15 years) |
1.4 |
120,000 |
76,000 |
The heavy use of drugs such as antibiotics and supportive therapies is evidence of continuous expansion in the neurosyphilis market. As the requirement for effective treatment grows, investments in these biologic categories increase. Thus, the inflated global trade of these components is a prominent indication of this sector’s enlargement. For instance, the worldwide export of antibiotics increased by 2.1% in 2022 from 2021, accounting for USD 10.7 billion. These organic chemicals included penicillin, which is known for its efficacy in treating syphilis and associated conditions. The top global importers in this industry were identified to be India, Italy, the U.S., Germany, and China: as per 2022 OEC data.
Neurosyphilis Sector: Growth Drivers and Challenges
Growth Drivers
- Ongoing developments in preventive therapeutics: Based on the acquired knowledge from several studies and clinical trials, the quality of offerings from the neurosyphilis market has improved significantly. In addition, enhanced diagnostic technologies such as molecular testing, PCR, and serological tests have helped pharma companies penetrate their products in this sector seamlessly. This has further leveraged the standards of innovative treatment solutions, influencing patients to invest. For instance, in February 2024, a study funded by the National Institute of Allergy and Infectious Diseases (NIAID) introduced a long-acting antiretroviral therapy (ART), combined with cabotegravir and rilpivirine.
- Financial support from the governing bodies: The contribution of authorized healthcare organizations in the widespread of the market is commendable. The rising cases of advanced syphilis dragged the focus of various government institutions on making related medical care more accessible for patients across the world. Their subsidiary policies and initiatives have notably encouraged industry leaders to be involved in this sector, working as a financial cushion. For instance, in January 2024, NC Medicaid announced an extension in coverage for imported benzathine benzylpenicillin (extencilline), authenticated by the FDA. This addition was aimed at covering the deficiency of Bicillin L-A.
Challenges
- Limited awareness about early diagnosis and intervention: The main reason behind the lack of adoption in the neurosyphilis market is delayed diagnosis. In cases of elongated ignorance on detecting disease progress impacts the effectiveness of available methodologies, losing consumer trust. On the other hand, suffering individuals often disobey the consistency in regular medication, which subsequently leads to the failure of designated regimens. However, educational programs and campaigns may be a suitable tactic to handle such issues.
- Absence of adequate healthcare accommodations: Stigma and barriers in medical fields associated with sexually transmitted infections (STIs) including the market are magnified by the shortage of dedicated infrastructure. This may worsen the situation and outcomes, hindering the onward motion of this sector. In addition, the complexity of handling comorbidities while managing this disorder may become challenging for legacy medical settings. This restricts future accretion and optimum implementation.
Neurosyphilis Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.8% |
|
Base Year Market Size (2024) |
USD 1.7 billion |
|
Forecast Year Market Size (2037) |
USD 3.7 billion |
|
Regional Scope |
|
Neurosyphilis Segmentation
Type (Metal Asymptomatic Neurosyphilis, Meningovascular Neurosyphilis, General Paresis, Tabes Dorsalis, Meningeal Neurosyphilis)
Metal asymptomatic neurosyphilis (ANS) segment is set to hold neurosyphilis market share of over 38.5% by the end of 2037. Advancements and the popularity of diagnostic measures have brought an evolution in treating this type of latent syphilis, where the clinical signs are usually absent. Being one of the most common syndromes among the other sub-categories, asymptomatic neurosyphilis gained priority on the list of HIV and MSM management. Additionally, the undetermined sequence of occurrences has upheld the importance of interventions for this type of syphilis. For instance, a study from a 2020 NLM article showcased a higher ANS frequency of 13% in HIV-negative serofast subjects.
Application (Hospital and Clinics, Medica Research Centers, Academic Institutes)
In terms of applications, the hospitals and clinics segment is predicted to hold the largest share in revenue from the neurosyphilis market by the end of 2037. This segment’s fluency is pledged by the growing clinical enrollment on consideration of better amenities. The enlarged network of consumer base for these organizations has made them the prime target for product suppliers in this category. The burden of neurological impairment is also a major growth factor in this segment. For instance, a study conducted in China disclosed an annual increment of 37.3% in disability-adjusted life years (DALYs) rate in five cities of China – 2023 NLM report. Further, it provides an example of expenditure, calculating USD 2501.1 to be the average cost of hospitalization.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Application |
|
|
Stage of Infection |
|
|
Diagnosis Method |
|
|
Treatment Type |
|
|
Route of Administration |
|
|
Patient Demographics |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportNeurosyphilis Industry - Regional Synopsis
North America Market Analysis
North America in neurosyphilis market is expected to capture around 47.3% revenue share by the end of 2037. The regional expansion is fueled by the increased availability of functional drugs and detection tools due to proactive participation in R&D. Developed countries such as the U.S. and Canada, are acquiring more approachable resources for every resident, opening new business opportunities. According to the 2022 OEC data, the U.S. was designed to be the top importer of penicillins and streptomycins, derivs, in dosage, majorly used for neurosyphilis, marking USD 411.0 million. It was accompanied by a remarkable export value of USD 96.5 million.
The U.S. is augmenting the market with its equipped screening and public health efforts from both government and private sources. It utilizes widely distributed diagnosis facilities and innovative detection methods to attract more interventions from global leaders in this sector. For instance, in October 2024, NOWDiagnostics collaborated with Labcorp to ensure exclusive distribution in the U.S. marketplace. This strategic partnership was intended to gain maximum adoption, by releasing the remote syphilis testing tool, First To Know for patients through Labcorp OnDemand in 2025.
The Canada neurosyphilis market is propelling onward with meticulous government initiatives and efforts to incorporate drug development. It is engaging and investing in several R&D projects to accelerate the procurement of faster- and longer-acting regimens for continued and reliable supply. For instance, in a report on research initiations across Canada, the Canadian HIV Trials Network (CTN) was specified for its flagship investment of USD 23.3 billion over the duration of 2019-2024. CTN was built to leverage the speed of knowledge intake and translation for commencing better clinical practices and guidelines for HIV/AIDS and other STBBI.
APAC Market Statistics
Asia Pacific is poised to gain traction in the neurosyphilis market with the fastest CAGR by the end of 2037. Its strong advocacy in pharmaceutical production and exploration adheres to greater opportunities for both domestic and international competitors. This region presents a broader scope of investments, fostered by the rising burden of neurosyphilis in countries including China and India. Furthermore, their potential to attract a larger consumer base through awareness campaigns and even healthcare access is boosting this sector.
India is garnering a profitable business atmosphere for the market by strengthening the supply-demand chain. With a remarkable reduction in HIV cases, the country is now focused on empowering its domestic manufacturing capabilities by enforcing trading incentives and subsidies. According to the PIB report, India achieved a 44% reduction in HIV incidences from 2010 to 2023. Another 2022 OEC report states that the nation ranked among the top largest exporters of penicillins, derivatives, in bulk, and salts in the world with a value of USD 253.0 million.
China also gained a leading position as the global supplier of antibiotics in the market. An OEC data showcased that the country recorded the highest export value of these therapeutics including penicillin in bulk, USD 1.1 billion in 2022. Moreover, the increasing nationwide burden of syphilis is also signifying developments in this field, embarking lucrative scopes of investment. According to a report from Cambridge researchers, the prevalence of syphilis in China escalated to 34.04 per 100,000 in 2021.
Companies Dominating the Neurosyphilis Landscape
- Abbott
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bayer
- Eli Lilly and Company
- GSK plc (GlaxoSmithKline)
- Novartis
- Pfizer
- Sanofi
- NOWDiagnostics, Inc.
The demographics of the market are revolutionizing the treatment approaches by bringing innovations. Many pharma companies have dedicated their resources to finding the most suitable route of administration and efficient formulations. They are also evolving their offerings in accordance with the changing consumer preferences. For instance, in March 2022, Janssen Pharmaceutical Companies, a subsidiary branch of Johnson & Johnson gained acceptance from the FDA to commercialize its CABENUVA (cabotegravir and rilpivirine). This combination therapy is capable of treating HIV-1 in virologically suppressed adolescents, who are 12 years of age or older, weigh at least 35 kg, and are on a stable ART regimen. Such key players are:
In the News
- In August 2024, NOWDiagnostics received De Novo Marketing Authorization from the FDA for its First To Know Syphilis Test. The allowance enabled rights to distribute the early diagnostic tool as an over-the-counter (OTC) product, offering faster and convenient in-home results for high-risk patients.
- In March 2024, GSK plc announced that its majorly owned company, ViiV Healthcare released a presentation on positive clinical data for its next-generation HIV portfolio at CROI 2024. The results from the phase I study disclosed new potentially effective formulations for preventing related conditions such as neurosyphilis.
Author Credits: Radhika Pawar
- Report ID: 7084
- Published Date: Jan 31, 2025
- Report Format: PDF, PPT
